AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35182101
Drug: Lean pork
RxNorm normalized name: Pork
DrugBank: Pork (DB10561)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean pork (156 g day-1)
Trial: 35182101
Drug: Chicken (active-control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicken (active-control, 156 g day-1)
Trial: 34910595
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.5 mg/kg, twice daily for 2 months
Trial: 35182418
Drug: MIB-626 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIB-626 1000 mg once daily
Trial: 35182418
Drug: MIB-626 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIB-626 1000 mg twice daily
Trial: 32816504
Drug: T-SIB (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-SIB (Treatment for Self-Injurious Behaviors)
Trial: 33264516
Drug: Bimagrumab 3
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab 3 mg/kg
Trial: 35679043
Drug: Intensive smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive smoking cessation treatment (up to 11 counseling sessions with free medications)
Trial: 35679043
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (up to 4 counseling sessions with medication advice)
Trial: 36383611
Drug: Colchicine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1.2 mg on day 1 followed by 0.6 mg daily for 13 days)
Trial: 32249621
Drug: Kd70 QW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kd70 QW (carfilzomib 70 mg/m2 once-weekly plus dexamethasone)
Trial: 32249621
Drug: Kd27 BIW
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kd27 BIW (carfilzomib 27 mg/m2 twice-weekly plus dexamethasone)
Trial: 38575409
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKIs)
Trial: 32597737
Drug: Integrative Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Cognitive Affective Therapy (ICAT-BED)
Trial: 32597737
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy Guided Self-Help (CBTgsh)
Trial: 34288280
Drug: ABCT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABCT + treatment as usual (TAU)
Trial: 33962825
Drug: Higher cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher cancer anxiety, being male, recent screening, family history of breast/prostate cancer, independence in activities of daily living
Trial: 36241697
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with CHOP (plus rituximab in CD20-positive lymphomas)
Trial: 34499135
Drug: Telecare case
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telecare case management program (weekly case management from a nurse via telephone and weekly video messages for 3 months)
Trial: 34499135
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (monthly social telephone calls)
Trial: 32672795
Drug: Pembrolizumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (2 mg/kg every 3 weeks, 10 mg/kg every 2 weeks, or 10 mg/kg every 3 weeks)
Trial: 34484887
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy for Migraine (MBCT-M)
Trial: 32340375
Drug: Increased daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased daily water intake (two additional 550 mL bottles of water consumed daily)
Trial: 33471487
Drug: ACE+TUDCA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE+TUDCA treatment for 8 weeks
Trial: 33471487
Drug: Sham ACE+TUDCA
RxNorm normalized name: TUDCA
DrugBank: Tauroursodeoxycholic acid (DB08834)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ACE+TUDCA treatment for 8 weeks
Trial: 35432194
Drug: Exenatide treatment
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide treatment
Trial: 34867786
Drug: Hypocaloric diet
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric diet plus placebo injections
Trial: 34265218
Drug: Multimodal prehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal prehabilitation including nutritional supplements (fish oil with vitamin D3 + whey protein with leucine), exercise and relaxation
Trial: 32683400
Drug: Insulin‐dependent Diabetes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin‐dependent Diabetes Mellitus (IDDM)
Trial: 32683400
Drug: Positive GAD65
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive GAD65 antibodies
Trial: 35688358
Drug: Pimitespib 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimitespib 160 mg/day
Trial: 34491652
Drug: Compound flumetasone
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound flumetasone ointment, applied twice a day for 3 weeks
Trial: 34018445
Drug: Lidocaine 4%
RxNorm normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 4% cream
Trial: 33421039
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group discussion session twice a week for 1 month)
Trial: 32410200
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (low‐level laser therapy) including red light (660 nm), infrared light (840 nm), and infrared laser applied on the first postoperative day
Trial: 35122442
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) using a diode laser, 808 nm, 250 mW; 16.25 J; 32.5 J cm-2
Trial: 35122442
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic gel (Benzocaine 20%)
Trial: 34754346
Drug: Levobupivacaine 0.5%
RxNorm normalized name: levobupivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.5% 15 ml plus ketamine 0.5 mg/kg (LK group)
Trial: 34754346
Drug: Levobupivacaine 0.5%
RxNorm normalized name: levobupivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.5% 15 ml plus 5 ml normal saline (L group)
Trial: 34233331
Drug: ACCEPT® (Additive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACCEPT® (Additive anthroposophic integrative medicine Cancer Concept of Early supportive or Palliative lung cancer Treatment) for 3 months with standard oncological care (SOC)
Trial: 36331570
Drug: Accelerated strategy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated strategy of renal-replacement therapy (RRT) initiation
Trial: 36331570
Drug: Standard strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard strategy of renal-replacement therapy (RRT) initiation
Trial: 34806624
Drug: Ultrasound-guided botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided botulinum toxin injection (50 units of botulinum toxin type A)
Trial: 34806624
Drug: Balloon catheter
RxNorm normalized name: Paclitaxel coated angioplasty balloon catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balloon catheter dilatation therapy (five times per week for two weeks)
Trial: 32034202
Drug: Inhaled milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled milrinone (5 mg) by mesh nebulization
Trial: 32034202
Drug: Inhaled milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled milrinone (5 mg) by jet nebulization
Trial: 35739713
Drug: True air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True air purification treatment
Trial: 35739713
Drug: Sham air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham air purification treatment
Trial: 33037810
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate 50 mg daily plus conventional hospital management
Trial: 32404731
Drug: Immunotherapy (2011-2013)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (2011-2013)
Trial: 32404731
Drug: Immunotherapy (2014)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (2014)
Trial: 32429720
Drug: Postoperative inosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative inosine pranobex immunotherapy
Trial: 32429720
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative immunotherapy
Trial: 36207508
Drug: Simultaneous initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Simultaneous initiation of lixisenatide and basal insulin (BI)
Trial: 36207508
Drug: Sequential initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sequential initiation of lixisenatide and basal insulin (BI)
Trial: 32325856
Drug: Yeast beta-glucan
RxNorm normalized name: Beta glucan
DrugBank: Yeast beta-D-glucan (DB19271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast beta-glucan (YBG) 250 mg/day
Trial: 32862111
Drug: IFN β‐1b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN β‐1b (250 mcg subcutaneously every other day for two consecutive weeks)
Trial: 32862111
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (national protocol medications: lopinavir/ritonavir or atazanavir/ritonavir plus hydroxychloroquine for 7–10 days)
Trial: 35123553
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel (PTX) with S-1
Trial: 34927213
Drug: Continuous orthodontic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous orthodontic force of 150 g applied for 8 weeks, reactivated after 28 days.
Trial: 34927213
Drug: Intermittent orthodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent orthodontic force (21 days on, 7 days off) of 150 g applied for 8 weeks.
Trial: 35384391
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplant (FMT) capsules, administered 5 times over 3 weeks
Trial: 35384391
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplant (FMT) capsules
Trial: 33234419
Drug: Sweet orange
RxNorm normalized name: sweet orange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweet orange inhalation
Trial: 33234419
Drug: Damask rose
RxNorm normalized name: damask rose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Damask rose inhalation
Trial: 35142713
Drug: Metformin (1561
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1561 ± 470 g·d‐1)
Trial: 35142713
Drug: Resistance Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance Training + Metformin (RT + MET)
Trial: 32743852
Drug: Lipid-lowering drugs
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering drugs
Trial: 32500569
Drug: Intra-operative fibrinogen
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operative fibrinogen concentrate 30 mg.kg-1 (maximum 2 g)
Trial: 32219329
Drug: Albiglutide 30
RxNorm normalized name: ALBIGLUTIDE 30MG/0.5ML INJ PEN 0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albiglutide 30 mg (up-titration to 50 mg at week 6)
Trial: 35152579
Drug: Bloodletting therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bloodletting therapy combined with auricular point sticking, given once every two days for 4 weeks.
Trial: 35152579
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of levocetirizine hydrochloride, 10 mL once daily for 4 weeks.
Trial: 33022987
Drug: Helianthus tuberosus
RxNorm normalized name: Helianthus Tuberosus Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helianthus tuberosus intake in the morning (5 g/day before breakfast)
Trial: 33022987
Drug: Helianthus tuberosus
RxNorm normalized name: Helianthus Tuberosus Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helianthus tuberosus intake in the evening (5 g/day before dinner)
Trial: 32149822
Drug: Preoperative prognostic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative prognostic factors including carbohydrate antigen 19-9, neoadjuvant treatment, tumor size, age, facility type, Charlson/Deyo score, primary site, and sex.
Trial: 32612213
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anti-inflammatory diet and cannabinoids
Trial: 35222266
Drug: Higher serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher serum folate concentrations (Q4≥33.0 ng/ml)
Trial: 35222266
Drug: Highest Ca/Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest Ca/Mg ratio quartile (≥5.02)
Trial: 35902851
Drug: Treatment-as-usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (TAU) in form of written information material
Trial: 34806975
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics (ceftazidime and tobramycin for 14 days, inhaled colistimethate sodium for 3 months)
Trial: 34806975
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (ciprofloxacin for 3 months, inhaled colistimethate sodium for 3 months)
Trial: 32317585
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg, oral, two times daily)
Trial: 35784742
Drug: LY06006 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY06006 60 mg
Trial: 38643086
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy (PT) alone
Trial: 35596030
Drug: Ertugliflozin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertugliflozin (5 and 15 mg pooled)
Trial: 34826124
Drug: CZP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 200 mg Q2W
Trial: 34192387
Drug: CZP 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 400 mg Q2W to CZP 200 mg Q2W
Trial: 34192387
Drug: Placebo to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to CZP 200 mg Q2W
Trial: 34192387
Drug: CZP 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 400 mg Q2W (escape arm)
Trial: 32932231
Drug: Caffeinated chewing
RxNorm normalized name: caffeine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated chewing gum (300 mg caffeine, 6 g sugars)
Trial: 32932231
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg caffeine, 0 g sugars)
Trial: 35438367
Drug: High fresh
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fresh gas flow (HFGF) at 4 L/min with sevoflurane vaporizer setting of 2.5%
Trial: 35438367
Drug: Low fresh
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fresh gas flow (LFGF) at 1 L/min with sevoflurane vaporizer setting of 8%
Trial: 34015228
Drug: Narrow Band
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow Band Ultraviolet B (NBUVB) with 311-313 nm, initial dose of 250 mJ/cm2, thrice a week for 8 weeks
Trial: 34058431
Drug: Sub-Tenon injection
RxNorm normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-Tenon injection of 0.15 ml of 0.01% MMC diluted with preservative free lidocaine 2% (n = 27)
Trial: 32661107
Drug: Glimepiride +
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride + Linagliptin 5 mg
Trial: 35594274
Drug: Minimal acupuncture
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal acupuncture treatment (8 sessions over 4 weeks)
Trial: 32993769
Drug: IOP-lowering medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IOP-lowering medication
Trial: 33113075
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) with a preventive oral care program (POCP), n = 25
Trial: 32894857
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg/day for 5 days)
Trial: 32839990
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium bicarbonate (4.26 g in 200 mL of water) plus oxytocin
Trial: 39415923
Drug: No antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombotic therapy
Trial: 35727042
Drug: Placebo-assisted therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-assisted therapy (Placebo-AT)
Trial: 32959996
Drug: High-intensity intervention
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity intervention (weekly multidisciplinary sessions)
Trial: 32436242
Drug: Oral ginger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ginger for dysmenorrhea
Trial: 32436242
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and topical ginger for DOMS
Trial: 32436242
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and topical ginger for knee AO
Trial: 32448159
Drug: School-based annual
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based annual mass drug administration (MDA) with praziquantel
Trial: 34705291
Drug: 81 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg/day aspirin for 4 weeks
Trial: 34705291
Drug: 325 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg/day aspirin for 4 weeks
Trial: 34705291
Drug: Aspirin exposure
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin exposure
Trial: 35013093
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of curcumin, resveratrol, zinc, magnesium, selenium, and vitamin D
Trial: 34088701
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human parathyroid hormone (PTH) (1-84)
Trial: 33218510
Drug: Myofascial induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial induction therapy (MIT)
Trial: 34957958
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drug treatments and instrumental physical therapy)
Trial: 34913362
Drug: MSC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSC therapy (infused at weeks 6 and 7 after transplantation, tacrolimus withdrawal at week 8)
Trial: 36347387
Drug: Standard tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tacrolimus dose (control group)
Trial: 33259244
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: vinorelbine 60 mg/m2 day 1 + day 8 in the first cycle followed by 80 mg/m2 day 1 + day 8 in the following cycles + capecitabine 1000 mg/m2 twice a day for days 1–14
Trial: 33259244
Drug: Arm B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: vinorelbine 50 mg three times a week + capecitabine 1000 mg/m2 twice a day for days 1–14